2020
DOI: 10.1111/cts.12880
|View full text |Cite
|
Sign up to set email alerts
|

The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study

Abstract: On March 11, 2020, the World Health Organization declared its assessment of coronavirus disease 2019 (COVID-19) as a global pandemic. However, specific anti-severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) drugs are still under development, and patients are managed by multiple complementary treatments. We performed a retrospective analysis to compare and evaluate the effect of low molecular weight heparin (LMWH) treatment on disease progression. For this purpose, the clinical records and laboratory… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
86
0
5

Year Published

2020
2020
2023
2023

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 134 publications
(93 citation statements)
references
References 39 publications
2
86
0
5
Order By: Relevance
“…Heparin exhibits anti-inflammatory effects by neutralizing damage associated cellular proteins, thereby stabilizing endothelial cell membrane, decreasing vascular leakage, and thrombus formation [36] , [37] . A report from China, administration of low molecular weight heparin reduced the IL-6 levels and improved anti-coagulation indices [38] .…”
Section: Discussionmentioning
confidence: 99%
“…Heparin exhibits anti-inflammatory effects by neutralizing damage associated cellular proteins, thereby stabilizing endothelial cell membrane, decreasing vascular leakage, and thrombus formation [36] , [37] . A report from China, administration of low molecular weight heparin reduced the IL-6 levels and improved anti-coagulation indices [38] .…”
Section: Discussionmentioning
confidence: 99%
“…10,[25][26][27] Standard treatment for COVID-19 in fact is based on the administration of several kind of drugs with multiple actions, in order to reduce inflammatory damage (ie, antivirals, immunomodulants, antibiotics, steroids, antithrombotics). Due to their pharmacological properties, heparinoids can fight SARS-CoV2 in multiple ways: a specific antiviral action of heparin toward SARS-CoV2 has been found in vitro and in vivo, 10,[23][24][25][26][27] as well a specific anti-inflammatory action of heparinoids and fondaparinux. 28,29 Of course, these additional properties should be added to the well-known antithrombotic actions of both drugs.…”
Section: Discussionmentioning
confidence: 99%
“…Elevated blood levels of cytokines and chemokines have been reported in patients with COVID-19 infection [ [4] , [5] , [6] , [7] ] that trigger a pro-inflammatory environment and severe tissue damage, thereby contributing to the adverse outcomes of this disease [ 8 ]. Inflammatory disease progression is usually associated with the production of reactive oxygen species (ROS) followed by oxidative stress [ 9 ].…”
Section: Introductionmentioning
confidence: 99%